FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

49 letters match. Newest first.

  1. Beaute Bounty

    FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.

    High risk
  2. Blue Horizon International, LLC

    FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.

    High risk
  3. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  4. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  5. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  6. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk
  7. Microvascular Tissue, Inc.

    FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.

    High risk
  8. Celularity, Inc

    FDA warns Celularity that Interfyl is an unapproved new drug and unlicensed biological product marketed for orthopedic and wound uses.

    High risk
  9. BioXtek LLC

    FDA says BioXtek's amniotic membrane products are unapproved new drugs and unlicensed biological products.

    High risk
  10. Lux Therapeutics LLC dba Ponya Therapeutics LLC

    FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.

    High risk
  11. New Life Medical Services, LLC

    FDA says New Life Medical Services sells unapproved umbilical-cord, amniotic-fluid, and exosome products as drugs.

    High risk
  12. Cellebration LLC

    FDA warns Cellebration LLC over unapproved cord-blood cellular products and refusal to provide requested records.

    High risk
  13. NuVida Medical LLC

    FDA says NuVida Medical sells unapproved, unlicensed tissue products for non-homologous wound care uses.

    High risk
  14. Platinum Biologics LLC

    FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.

    High risk
  15. Innate Healthcare Institute

    FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.

    High risk
  16. InVia Fertility Specialists, PLLC

    FDA warned InVia Fertility Specialists over reproductive tissue donor eligibility and missing infectious disease testing.

    High risk
  17. Skye Biologics Holdings LLC

    FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.

    High risk
  18. Sperm Bank, Inc. dba Fertility Center of California

    FDA warned Sperm Bank, Inc. dba Fertility Center of California over donor semen released without required infectious-disease testing and screening.

    High risk
  19. BioStem Life Sciences

    FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.

    High risk
  20. Chara Biologics, Inc.

    FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.

    High risk
  21. Evolutionary Biologics Inc.

    FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.

    High risk
  22. Pinnacle Transplant Technologies, LLC

    FDA warns Pinnacle Transplant Technologies over unapproved injectable amniotic products and sterility CGMP failures.

    High risk
  23. Amnio Technology, LLC

    FDA warned Amnio Technology over unapproved injectable amniotic products and serious manufacturing deviations at its Phoenix facility.

    High risk
  24. Mother Stem Institute, Corp.

    FDA warns Mother Stem Institute over unapproved fat-derived SVF 'stem cell' biologic marketed for serious diseases.

    High risk
  25. Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.

    FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.

    High risk
  26. New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank

    FDA warns New Mexico eye bank over distributing eye tissue from two donors with sepsis.

    High risk
  27. Indiana Lions Eye Bank, Inc. dba VisionFirst Indiana Lions Eye Bank

    Indiana Lions Eye Bank distributed ocular tissue from donors with sepsis after failing to screen them as ineligible.

    High risk
  28. Neobiosis, LLC

    FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.

    High risk
  29. Akan Biosciences, Inc.

    FDA warned Akan Biosciences over unapproved Ayama injectable and donor-screening failures.

    High risk
  30. Washington Fertility Center

    FDA warned Washington Fertility Center about incomplete donor eligibility screening and testing for oocytes, semen, and embryos.

    High risk
  31. MiMedx Group, Inc.

    FDA cites MiMedx for marketing placental product AXIOFILL without BLA or IND and for CGMP failures.

    High risk
  32. Signature Biologics, LLC

    FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.

    High risk
  33. RenatiLabs Inc.

    RenatiLabs marketed WJMAX, a human umbilical cord-derived biologic, without a license and released a lot that failed sterility testing.

    High risk
  34. Stratus Biosystems, LLC dba CellGenuity Regenerative Science

    FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.

    High risk
  35. The New Hope Center for Reproductive Medicine

    FDA warns Virginia Beach fertility center over incomplete donor screening and testing for reproductive tissue.

    High risk
  36. Row1 Inc. dba Regenative Labs

    FDA warned Regenative Labs that its umbilical cord products are unlicensed drugs, made under serious sterility and manufacturing failures.

    High risk
  37. Mark S. Denker, M.D., PA dba Palm Beach Fertility Center

    FDA warns Boca Raton fertility center over failures to screen sperm and egg donors for infectious disease risk.

    High risk
  38. Cryos International USA LLC

    Cryos International USA released and distributed anonymous donor semen without required infectious disease testing and quarantine.

    High risk
  39. Invitrx Therapeutics, Inc.

    Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.

    High risk
  40. BioLab Sciences, Inc.

    FDA warned BioLab Sciences that its injected amniotic fluid and skin products were unapproved biologics with serious manufacturing violations.

    High risk
  41. Vitti Labs, LLC

    FDA warns Vitti Labs over unapproved umbilical cord and amniotic membrane products and sterile manufacturing failures.

    High risk
  42. Zhang Medical P.C. dba New Hope Fertility Center

    New Hope Fertility Center failed to properly screen and test oocyte and semen donors for communicable diseases, FDA says.

    High risk
  43. Re-Gen Active Lab, Inc.

    FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.

    High risk
  44. OsteoLife Biomedical I LLC

    FDA warned OsteoLife Biomedical over unvalidated processing and microbial contamination of human bone tissue products, including distributed batches.

    High risk
  45. Smart Surgical, Inc dba Burst Biologics

    Burst Biologics distributed unapproved umbilical cord blood products as drugs while failing sterility and donor-screening rules.

    High risk
  46. Cooper Institute

    FDA warned Houston fertility clinic Cooper Institute that it failed to test and screen oocyte donors for infectious diseases.

    High risk
  47. Surgenex LLC

    FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.

    High risk
  48. Utah Cord Bank LLC dba Utah Cell Bank

    Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.

    High risk
  49. Utah Cord Bank LLC

    FDA cited Utah Cord Bank for unvalidated cord blood processing, missing environmental monitoring, procedures, and records after a February 2021 inspection.

    High risk